The phase I study of the combined immunotherapy using alpha-galactosylceramide pulsed antigen presenting cells and tumor-specific peptide pulsed dendritic cells for patients with advanced head and neck mucosal melanoma
Not Applicable
- Conditions
- Head and neck mucosal malignant melanoma
- Registration Number
- JPRN-UMIN000011508
- Lead Sponsor
- Department of Otorynolaryngology, Head and Neck Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
Past histry of hepatitis; a positive response for HBs antigen/HCT antibody/HIV antibody/HTL-V1 antibody; recieived concurrent corticosteroid therapy; pregnancy or lactation; antoimmune disease; infection; uncontrolled diabetes mellitus; pulmonary fibrosis; serious cardiac disease; double cancer; large pleural effusions: brain metastasis judgement of physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety profile
- Secondary Outcome Measures
Name Time Method